Read by QxMD icon Read

Thrombocytopenia in bone metastasis prostate cancer

Bide Xiong, Fang Liu, Elizabeth Garber, James Wheeler
225 Background: The ALSYMCA (Alpharadin in Symptomatic Prostate Cancer) trial was a phase III, placebo controlled, randomized trial in which 921 men with bone metastasis from hormone refractory prostate cancer (HRPC) were randomly assigned to receive radium-223 (Ra-223) or placebo. Ra-223 produced a 30% survival benefit, with a median survival of 14.9 months compared to 11.3 months for patients treated with a placebo, which led to FDA approval in 2013. METHODS: We identified through the nuclear medicine records 11 patients who started Ra-223 between March 15, 2013 and December 10, 2015...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Mutahir Tunio, Mushabbab Al Asiri, Abdulrehman Al Hadab, Yasser Bayoumi
BACKGROUND: A meta-analysis was conducted to assess the impact of radiopharmaceuticals (RPs) in castration-resistant prostate cancer (CRPC) on pain control, symptomatic skeletal events (SSEs), toxicity profile, quality of life (QoL), and overall survival (OS). MATERIALS AND METHODS: The PubMed/MEDLINE, CANCERLIT, EMBASE, Cochrane Library database, and other search engines were searched to identify randomized controlled trials (RCTs) comparing RPs with control (placebo or radiation therapy) in metastatic CRPC...
2015: Drug Design, Development and Therapy
Nobuki Furubayashi, Takahito Negishi, Shintaro Ura, Yoshiki Hirai, Motonobu Nakamura
The aim of the present study was to evaluate the palliative effects and adverse events of strontium-89 (Sr-89) in patients with bone metastasis from prostate cancer. A total of 18 patients with prostate cancer and painful bone metastases, as diagnosed on bone scintigraphy, who were treated with Sr-89 at the National Kyushu Cancer Center between February, 2008 and April, 2014 were reviewed. Of the 18 subjects, 13 (72.2%) achieved a pain response, whereas 5 were classified as pain non-responders (27.8%). According to a logistic regression analysis, the pre-administration characteristics, including age, prostate-specific antigen (PSA), alkaline phosphatase (ALP), history of bone-modifying agent administration, opioid use or palliative radiation therapy, time after the combined androgen blockade nadir and time since the pain onset, were not found to be significant predictors of the pain response...
January 2015: Molecular and Clinical Oncology
Betul Bolat Kucukzeybek, Aylin Orgen Calli, Yuksel Kucukzeybek, Sadi Bener, Yelda Dere, Ahmet Dirican, Kadriye Bahriye Payzin, Fusun Ozdemirkiran, Mustafa Oktay Tarhan
BACKGROUND: Bone marrow biopsy is widely used method for diagnosis, follow-up and staging of hemato-oncologic diseases. This procedure is also used for determining the bone marrow metastasis in patients with solid tumors. In this study, clinical, hematological, and pathological features of 58 patients with bone marrow metastases diagnosed by bone marrow biopsies were examined retrospectively MATERIALS AND METHODS: Among 3345 bone marrow biopsies performed in our hospital between January 2006 and August 2013, 58 cases with solid tumor metastasized to bone marrow were included in this study...
July 2014: Indian Journal of Pathology & Microbiology
Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J George
BACKGROUND: Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity of energy per track length with short tissue penetration. OBJECTIVE: This review describes the mechanism, radiobiology, and preclinical development of (223)Ra and discusses the clinical data currently available regarding its safety and efficacy profile...
2013: Cancer Management and Research
Hideaki Miyake, Iori Sakai, Ken-ichi Harada, Mototsugu Muramaki, Masato Fujisawa
OBJECTIVES: The objective of this study was to evaluate the significance of docetaxel-based chemotherapy in elderly Japanese men with metastatic castration-resistant prostate cancer (CRPC). MATERIALS AND METHODS: This study included a total of 159 consecutive patients aged≥75 years with mCRPC who were treated with docetaxel-based chemotherapy. The efficacy and tolerability of this therapy were retrospectively analyzed. RESULTS: In these 159 patients, the median age and prostate-specific antigen (PSA) level before docetaxel-based chemotherapy were 78 years and 44...
December 2012: International Urology and Nephrology
Glenn Liu, Yu-Hui Chen, Robert Dipaola, Michael Carducci, George Wilding
UNLABELLED: Ixabepilone is an epothilone B analogue with activity in a variety of solid malignancies, including prostate cancer. The main dose-limiting toxicity of ixabepilone is myelosuppression when administered by using an every 3-week schedule. Here we evaluate the activity of a weekly ixabepilone in men with metastatic castrate-resistant prostate cancer to minimize hematologic toxicity. PURPOSE: BMS-247550 (ixabepilone) is an epothilone B analogue with activity in taxane-resistant cancer cell lines...
June 2012: Clinical Genitourinary Cancer
Keiji Kato, Kanji Nagahama, Yusuke Yagibashi, Masakazu Yamamoto, Hiroshi Kanamaru, Hirokazu Hirata
A 76-year-old man underwent radical prostatectomy under the diagnosis of stage C prostate cancer (cT3bN0M0, Gleason score 3+4) in 1999. Endocrine treatment for postoperative biochemical failure started in 2001. He was admitted to our hospital because of general fatigue and multiple bone pain with a prostate specific antigen (PSA) level of 1,141 ng/ml in August 2009. On admission, no metastasis was detected on bone scintigraphy or computed tomography. Bone marrow biopsy was finally performed for the assessment of bone metastasis after PSA further increased to 8,679 ng/ml with the manifestation of severe anemia and thrombocytopenia...
June 2011: Hinyokika Kiyo. Acta Urologica Japonica
Takuma Kato, Norihito Yamamoto, Yuuki Matsuoka, Yoshihiro Kuwata, Teruhisa Taoka, Naomi Kazuki, Yoshio Kushida, Yoshiyuki Kakehi
Disseminated carcinomatosis of the bone marrow is caused by metastasis to the bone marrow and can cause disseminated intravascular coagulation (DIC), leucoerythroblastosis, and microangiopathic hemolytic anemia (MHA). The prognosis of this syndrome is poor. We report herein two rare cases of disseminated carcinomatosis of the bone marrow in association with prostate cancer. Case 1 involved a 61-year-old man admitted to our department with elevated prostate-specific antigen (PSA) levels. Prostate biopsy revealed prostate cancer, and imaging studies were performed...
January 2011: Nihon Hinyōkika Gakkai Zasshi. the Japanese Journal of Urology
A Fléchon, D Pouessel, C Ferlay, D Perol, P Beuzeboc, G Gravis, F Joly, S Oudard, G Deplanque, S Zanetta, P Fargeot, F Priou, J P Droz, S Culine
BACKGROUND: In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine differentiation in 20% of cases. PATIENTS AND METHODS: We assessed the efficacy and toxicity of a platinum-based chemotherapy regimen in mCRPC patients with either neuroendocrine differentiation defined by high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) or visceral metastases. Patients received the combination of carboplatin and etoposide every 3 weeks...
November 2011: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Noriyoshi Miura, Kosaku Numata, Yoshito Kusuhara, Akitomi Shirato, Katsuyoshi Hashine, Yoshiteru Sumiyoshi
OBJECTIVE: To evaluate the efficacy and toxicity of docetaxel plus prednisolone treatment in Japanese patients with hormone-refractory prostate cancer (HRPC). METHODS: From April 2004 through August 2008, we used docetaxel plus prednisolone to treat 55 HRPC patients (median age, 72 years). Eighteen patients (32.7%) had measurable soft tissue lesions, whereas 52 patients (94.5%) had bone metastases. During the 21-day treatment cycle, docetaxel (70 mg/m(2)) was administered once every 21 days and oral prednisolone (5 mg), twice daily...
November 2010: Japanese Journal of Clinical Oncology
Jianqing Lin, Victoria J Sinibaldi, Michael A Carducci, Samuel Denmeade, Danny Song, Theodore Deweese, Mario A Eisenberger
BACKGROUND: This study was designed to evaluate toxicity and preliminary efficacy of 2 cycles of concomitant standard dose/schedule of (153)Sm-lexidronam plus Q 3 weeks schedule escalating doses of docetaxel in metastatic castration-resistant prostate cancer (mCRPC). METHODS: mCRPC patients with progressive bone metastases were treated in 4 cohorts. Docetaxel doses were escalated from 50, 50, 0 mg/m(2) (on days 1, 22, 43, per 12-week cycle) to 75, 75, 75 mg/m(2)...
November 2011: Urologic Oncology
Nobuyuki Kikuno, Shinji Urakami, Shigeru Nakamura, Takeo Hiraoka, Taijyu Hyuga, Naoko Arichi, Kouji Wake, Masahiro Sumura, Tatsuaki Yoneda, Hirofumi Kishi, Kazushi Shigeno, Hiroaki Shiina, Mikio Igawa
OBJECTIVES: To determine the safety and efficacy of combination chemotherapy with docetaxel (DTX), estramustine phosphate (EMP), and carboplatin (CBDCA) in patients with hormone-refractory prostate cancer (HRPC). METHODS: This study included a total of 40 HRPC patients. We evaluated the activity of the following schedule: weekly DTX 30 mg/m(2) iv, daily EMP 10mg/kg po, and CBDCA AUC=6 iv on day 1 of a every 4-wk cycle. Treatment was continued until disease progression or excessive toxicity...
May 2007: European Urology
Jennifer E Koblinski, Benjamin R Kaplan-Singer, Sherilyn J VanOsdol, Michael Wu, Jean A Engbring, Songlin Wang, Corinne M Goldsmith, John T Piper, Jaroslav G Vostal, John F Harms, Danny R Welch, Hynda K Kleinman
Skeletal metastases occur with high incidence in patients with breast cancer and cause long-term skeletal morbidity. Osteonectin (SPARC, BM-40) is a bone matrix factor that is an in vitro chemoattractant for breast and prostate cancer cells. Increased expression of osteonectin is found in malignant breast tumors. We infected MDA-231 breast cancer cells with an adenovirus expressing osteonectin to examine the role of osteonectin expression in breast cancer cells and its effect on metastasis, in particular to bone...
August 15, 2005: Cancer Research
Mohammad Reza Safarinejad
PURPOSE: To investigate more effective chemotherapy against hormone refractory prostate cancer (HRPC) with the combination of estramustine (EM), docetaxel, and suramin. PATIENTS AND METHODS: A total of 42 patients with symptomatic, progressive HRPC were included in this study. We evaluated the activity of the following schedule: EM 10 mg/kg orally daily on Days 1 to 21 every 28 days, docetaxel 70 mg/m(2) IV on Day 2 every 28 days and a total doses of 2150 mg of suramin in every cycle...
March 2005: Urologic Oncology
Shin Koga
For a long time fibrinopeptide A(FPA), fibrinopeptide B(FPB), D-dimer, FM test, serum FDP, and thrombin anti-thrombin complex(TAT) are being used as molecular markers to for sure diagnose hypercoagulable state and thrombus formation. Indeed these molecular markers are very useful for diagnosing thrombus formation, disseminated intravascular coagulation(DIC), and the indicator of treatment of DIC. But these molecular parameters are not enough and difficult for prognosis of the disease or predicting the complication of patients as the most important subject for clinicians...
April 2004: Rinsho Byori. the Japanese Journal of Clinical Pathology
K N Chi, M E Gleave, R Klasa, N Murray, C Bryce, D E Lopes de Menezes, S D'Aloisio, A W Tolcher
PURPOSE: Bcl-2 is a negative prognostic indicator in prostate cancer, implicated in the development of androgen independence and treatment resistance, and is overexpressed in hormone-refractory prostate cancer (HRPC). Genasense is a phosphorothioate antisense oligonucleotide complementary to the bcl-2 mRNA open reading frame that in preclinical studies has shown significant activity in inhibiting expression of Bcl-2, delaying androgen independence, and improving chemosensitivity in prostate and other cancer models...
December 2001: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
P Lissoni, M Cazzaniga, G Tancini, E Scardino, R Musci, S Barni, M Maffezzini, T Meroni, F Rocco, A Conti, G Maestroni
OBJECTIVE: Experimental and preliminary clinical studies have suggested that the pineal hormone melatonin (MLT) may stimulate hormone receptor expression on both normal and cancer cells. Moreover, MLT has appeared to inhibit the growth of some cancer cell lines, including prostate cancer, either by exerting a direct cytostatic action, or by decreasing the endogenous production of some tumor growth factors, such as prolactin (PRL) and insulin-like growth factor-1 (IGF-1). On this basis, a study was carried out to evaluate the clinical efficacy of a neuroendocrine combination consisting of the LHRH analogue triptorelin plus MLT in metastatic prostate cancer progressing on triptorelin alone...
1997: European Urology
O Sartor, M Cooper, M Weinberger, D Headlee, A Thibault, A Tompkins, S Steinberg, W D Figg, W M Linehan, C E Myers
BACKGROUND: The best treatment for patients with "hormone-refractory" metastatic prostate cancer is unclear, particularly in patients for whom suramin and hydrocortisone have failed. PURPOSE: We investigated a combination of flutamide withdrawal and aminoglutethimide in suramin- and hydrocortisone-pretreated patients with "hormone-refractory" prostate cancer. METHODS: Twenty-nine patients with metastatic prostate cancer were treated with simultaneous flutamide withdrawal and aminoglutethimide (250 mg given orally four times daily)...
February 2, 1994: Journal of the National Cancer Institute
R W Edland
No abstract text is available yet for this article.
March 1974: American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"